CIPLA USA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA USA, and when can generic versions of CIPLA USA drugs launch?
CIPLA USA has one approved drug.
There are four US patents protecting CIPLA USA drugs. There is one tentative approval on CIPLA USA drugs.
There are twenty-three patent family members on CIPLA USA drugs in twenty-one countries.
Summary for CIPLA USA
| International Patents: | 23 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for CIPLA USA: | See patent lawsuits for CIPLA USA |
Drugs and US Patents for CIPLA USA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 9,266,919 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 8,383,596 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 9,688,711 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | 8,822,424 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cipla Usa | ZEMDRI | plazomicin sulfate | SOLUTION;INTRAVENOUS | 210303-001 | Jun 25, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
